193 related articles for article (PubMed ID: 22119168)
1. Myeloid differentiation 2 as a therapeutic target of inflammatory disorders.
Park SH; Kim ND; Jung JK; Lee CK; Han SB; Kim Y
Pharmacol Ther; 2012 Mar; 133(3):291-8. PubMed ID: 22119168
[TBL] [Abstract][Full Text] [Related]
2. Targeting myeloid differentiation 2 for treatment of sepsis.
Duan G; Zhu J; Xu J; Liu Y
Front Biosci (Landmark Ed); 2014 Jun; 19(6):904-15. PubMed ID: 24896325
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.
Kim HM; Park BS; Kim JI; Kim SE; Lee J; Oh SC; Enkhbayar P; Matsushima N; Lee H; Yoo OJ; Lee JO
Cell; 2007 Sep; 130(5):906-17. PubMed ID: 17803912
[TBL] [Abstract][Full Text] [Related]
4. MD-2 as the target of curcumin in the inhibition of response to LPS.
Gradisar H; Keber MM; Pristovsek P; Jerala R
J Leukoc Biol; 2007 Oct; 82(4):968-74. PubMed ID: 17609337
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
Mishra V; Pathak C
J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists.
Peri F; Piazza M
Biotechnol Adv; 2012; 30(1):251-60. PubMed ID: 21664961
[TBL] [Abstract][Full Text] [Related]
7. R-form LPS, the master key to the activation ofTLR4/MD-2-positive cells.
Huber M; Kalis C; Keck S; Jiang Z; Georgel P; Du X; Shamel L; Sovath S; Mudd S; Beutler B; Galanos C; Freudenberg MA
Eur J Immunol; 2006 Mar; 36(3):701-11. PubMed ID: 16506285
[TBL] [Abstract][Full Text] [Related]
8. The antagonist activity of lipid IVa on the stimulation by lipid A of TNF-alpha production from canine blood mononuclear cells.
Takasawa K; Kano R; Maruyama H; Hasegawa A; Kamata H
Vet Immunol Immunopathol; 2011 Sep; 143(1-2):167-9. PubMed ID: 21782253
[TBL] [Abstract][Full Text] [Related]
9. Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics.
Heine H; Adanitsch F; Peternelj TT; Haegman M; Kasper C; Ittig S; Beyaert R; Jerala R; Zamyatina A
Front Immunol; 2021; 12():631797. PubMed ID: 33815382
[TBL] [Abstract][Full Text] [Related]
10. Human TLR4 polymorphism D299G/T399I alters TLR4/MD-2 conformation and response to a weak ligand monophosphoryl lipid A.
Yamakawa N; Ohto U; Akashi-Takamura S; Takahashi K; Saitoh S; Tanimura N; Suganami T; Ogawa Y; Shibata T; Shimizu T; Miyake K
Int Immunol; 2013 Jan; 25(1):45-52. PubMed ID: 22962435
[TBL] [Abstract][Full Text] [Related]
11. Activation of Human Toll-like Receptor 4 (TLR4)·Myeloid Differentiation Factor 2 (MD-2) by Hypoacylated Lipopolysaccharide from a Clinical Isolate of Burkholderia cenocepacia.
Di Lorenzo F; Kubik Ł; Oblak A; Lorè NI; Cigana C; Lanzetta R; Parrilli M; Hamad MA; De Soyza A; Silipo A; Jerala R; Bragonzi A; Valvano MA; Martín-Santamaría S; Molinaro A
J Biol Chem; 2015 Aug; 290(35):21305-19. PubMed ID: 26160169
[TBL] [Abstract][Full Text] [Related]
12. The molecular mechanism of species-specific recognition of lipopolysaccharides by the MD-2/TLR4 receptor complex.
Oblak A; Jerala R
Mol Immunol; 2015 Feb; 63(2):134-42. PubMed ID: 25037631
[TBL] [Abstract][Full Text] [Related]
13. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization.
Saitoh S; Akashi S; Yamada T; Tanimura N; Kobayashi M; Konno K; Matsumoto F; Fukase K; Kusumoto S; Nagai Y; Kusumoto Y; Kosugi A; Miyake K
Int Immunol; 2004 Jul; 16(7):961-9. PubMed ID: 15184344
[TBL] [Abstract][Full Text] [Related]
14. Myeloid differentiation protein 2 silencing decreases LPS-induced cytokine production and TLR4/MyD88 pathway activity in alveolar macrophages.
Ren W; Hu L; Hua F; Jin J; Wang Y; Zhu L
Immunol Lett; 2011 Dec; 141(1):94-101. PubMed ID: 21849156
[TBL] [Abstract][Full Text] [Related]
15. MD-2.
Visintin A; Iliev DB; Monks BG; Halmen KA; Golenbock DT
Immunobiology; 2006; 211(6-8):437-47. PubMed ID: 16920483
[TBL] [Abstract][Full Text] [Related]
16. Bordetella pertussis Lipid A Recognition by Toll-like Receptor 4 and MD-2 Is Dependent on Distinct Charged and Uncharged Interfaces.
Maeshima N; Evans-Atkinson T; Hajjar AM; Fernandez RC
J Biol Chem; 2015 May; 290(21):13440-53. PubMed ID: 25837248
[TBL] [Abstract][Full Text] [Related]
17. Mechanism regulating cell surface expression and activation of Toll-like receptor 4.
Saitoh S; Miyake K
Chem Rec; 2006; 6(6):311-9. PubMed ID: 17304555
[TBL] [Abstract][Full Text] [Related]
18. MD-2 as the target of nonlipid chalcone in the inhibition of endotoxin LPS-induced TLR4 activity.
Roh E; Lee HS; Kwak JA; Hong JT; Nam SY; Jung SH; Lee JY; Kim ND; Han SB; Kim Y
J Infect Dis; 2011 Apr; 203(7):1012-20. PubMed ID: 21402551
[TBL] [Abstract][Full Text] [Related]
19. Tetraacylated lipid A and paclitaxel-selective activation of TLR4/MD-2 conferred through hydrophobic interactions.
Resman N; Oblak A; Gioannini TL; Weiss JP; Jerala R
J Immunol; 2014 Feb; 192(4):1887-95. PubMed ID: 24420921
[TBL] [Abstract][Full Text] [Related]
20. Innate recognition of lipopolysaccharide by Toll-like receptor 4/MD-2 and RP105/MD-1.
Miyake K; Ogata H; Nagai Y; Akashi S; Kimoto M
J Endotoxin Res; 2000; 6(5):389-91. PubMed ID: 11521060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
